Advertisement

Biochemical Brain Markers in Excited Delirium Deaths

  • Deborah C. Mash
Chapter

Over the past decade, increased attention has been paid to the sudden deaths of some highly agitated subjects held in police custody, which were restrained or incapacitated by CEWs. Medical examiners often have extreme difficulty in identifying the cause of death, but frequently drug intoxication is considered a contributing factor. The symptoms of excited delirium include bizarre and/or aggressive behavior, shouting, paranoia, panic, violence toward others, unexpected physical strength, and hyperthermia. Throughout the United States and Canada, these cases are frequently associated with cocaine or methamphetamine abuse. Acute exhaustive mania and sudden death presents with behavioral signs and symptoms that are the same as in cases of cocaine excited delirium. However, the forensic autopsies fail to demonstrate a history of illicit drug use or positive toxicologic basis for the diagnosis. The striking parallel in behavioral symptoms between the manner of sudden death involving unusual behavior in these individuals suggests that a genetic brain disorder may be the precipitating cause of delirium and death. While the precise cause and mechanism of lethality remains controversial, we have demonstrated that there are network-level changes in dopaminergic synaptic markers in brain that identify and help to confirm the occurrence of the excited delirium syndrome. Characterization of adaptive and maladaptive functional interactions among brain pathways is a critical step towards development of evidence-based biomarkers of excited delirium.

Keywords

Dopamine Transporter Core Body Temperature Neuroleptic Malignant Syndrome Neurochemical Pathology Chronic Cocaine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The author would like to acknowledge the expert technical assistance of Margaret Basile, M.S., Qinjie Ouyang, B.A., and John Pablo, Ph.D. The author is grateful to Charles Wetli, M.D., W. Lee Hearn, Ph.D. and A. James Ruttenber, M.D., Ph.D., for their long-standing collaboration, guidance and helpful discussions on the topic of in custody excited delirium deaths. Julie K. Staley, Ph.D. contributed to the characterization of dopaminergic synaptic markers in postmortem brains of cocaine abusers and to many of the original publications cited here. Charles P. Wetli, M.D. and Steven B. Karch, M.D. have contributed to the author's views on excited delirium and to the application of the research findings in postmortem brain to forensic biology. This work was supported by a USPHS grant from the National Institute on Drug Abuse (DA06627).

References

  1. 1.
    Satel SL, Seibyl JP, Charney DS. Prolonged cocaine psychosis implies underlying major psychopathology. J Clin Psychiatry 1991;52:349–50.PubMedGoogle Scholar
  2. 2.
    Satel SL, Southwick SM, Gawin FH. Clinical features of cocaine-induced paranoia. Am J Psychiatry 1991;148:495–8.PubMedGoogle Scholar
  3. 3.
    Angrist BM. Cocaine in the context of prior central nervous system stimulant epidemics. In: Volkow N, Swann AC, eds. Cocaine in the Brain (Mind in Medicine Series): Rutgers University Press, 1990:7–24.Google Scholar
  4. 4.
    Wetli CV, Fishbain DA. Cocaine-induced psychosis and sudden death in recreational cocaine users. J Forensic Sci 1985;30:873–80.PubMedGoogle Scholar
  5. 5.
    Wetli CV. Excited delirium. In: Payne-James J, et al., eds. Encyclopedia of Forensic and Legal Medicine. Elsevier, 2005:276–281.Google Scholar
  6. 6.
    Wetli CV, Mash D, Karch SB. Cocaine-associated agitated delirium and the neuroleptic malignant syndrome. Am J Emerg Med 1996;14:425–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Ruttenber AJ, Lawler-Heavner J, Yin M, Wetli CV, Hearn WL, Mash DC. Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity. J Forensic Sci 1997;42:25–31.PubMedGoogle Scholar
  8. 8.
    Ross DL. Factors associated with excited delirium deaths in police custody. Mod Pathol 1998;11:1127–37.PubMedGoogle Scholar
  9. 9.
    Reay DT, Howard JD, Fligner CL, Ward RJ. Effects of positional restraint on oxygen saturation and heart rate following exercise. Am J Forensic Med Pathol 1988;9:16–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Karch SB, Stephens BG. Drug abusers who die during arrest or in custody. J R Soc Med 1999;92:110–3.PubMedGoogle Scholar
  11. 11.
    Stratton SJ, Rogers C, Brickett K, Gruzinski G. Factors associated with sudden death of individuals requiring restraint for excited delirium. Am J Emerg Med 2001;19:187–91.PubMedCrossRefGoogle Scholar
  12. 12.
    DiMaio TG, DiMaio VJM. Excited Delirium Syndrome: Cause of Death and Prevention. Taylor and Francis, New York, 2006.Google Scholar
  13. 13.
    Bell LV. On a form of disease resembling some advanced stages of mania and fever. Am J Insanity 1849;6:97–127.Google Scholar
  14. 14.
    Wetli CV, Natarajan GA. CUSTODY | Death in, United States of America. In: Payne-James J, Byard R, Corey T, Henderson C, eds. Encyclopedia of Forensic and Legal Medicine. Elsevier, 2005:65–73.Google Scholar
  15. 15.
    Kosten TR, Kleber HD. Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse 1988;14:335–46.PubMedCrossRefGoogle Scholar
  16. 16.
    Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. Jama 1985;254:2792–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137–45.PubMedGoogle Scholar
  18. 18.
    Caroff SN, Campbell EC, Sullivan KA. Neuroleptic malignant syndrome in elderly patients. Expert Rev Neurother 2007;7:423–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Strawn JR, Keck PE, Jr., Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Stephens BG, Jentzen JM, Karch S, Mash DC, Wetli CV. Criteria for the interpretation of cocaine levels in human biological samples and their relation to the cause of death. Am J Forensic Med Pathol 2004;25:1–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Stephens BG, Jentzen JM, Karch S, Wetli CV, Mash DC. National Association of Medical Examiners position paper on the certification of cocaine-related deaths. Am J Forensic Med Pathol 2004;25:11–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Ruttenber AJ, McAnally HB, Wetli CV. Cocaine-associated rhabdomyolysis and excited delirium: different stages of the same syndrome. Am J Forensic Med Pathol 1999;20:120–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Staley JK, Hearn WL, Ruttenber AJ, Wetli CV, Mash DC. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther 1994;271:1678–85.PubMedGoogle Scholar
  24. 24.
    Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Mash DC. Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse 1995;21:364–72.PubMedCrossRefGoogle Scholar
  25. 25.
    Mash DC, Pablo J, Ouyang Q, Hearn WL, Izenwasser S. Dopamine transport function is elevated in cocaine users. J Neurochem 2002;81:292–300.PubMedCrossRefGoogle Scholar
  26. 26.
    Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237:1219–23.PubMedCrossRefGoogle Scholar
  27. 27.
    Mortensen OV, Amara SG. Dynamic regulation of the dopamine transporter. Eur J Pharmacol 2003;479:159–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Uhl GR. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord 2003;18 Suppl 7:S71–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. Aaps J 2005;7:E847–51.PubMedCrossRefGoogle Scholar
  30. 30.
    Pristupa ZB, Wilson JM, Hoffman BJ, Kish SJ, Niznik HB. Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol 1994;45:125–35.PubMedGoogle Scholar
  31. 31.
    Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 1994;11:195–200.PubMedCrossRefGoogle Scholar
  32. 32.
    van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB. Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 2002;159:309–12.PubMedCrossRefGoogle Scholar
  33. 33.
    van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005;46:745–51.PubMedGoogle Scholar
  34. 34.
    Boden AG, Harris MC, Parkes MJ. The preoptic area in the hypothalamus is the source of the additional respiratory drive at raised body temperature in anaesthetised rats. Exp Physiol 2000;85:527–37.PubMedCrossRefGoogle Scholar
  35. 35.
    Costentin J, Duterte-Boucher D, Panissaud C, Michael-Titus A. Dopamine D1 and D2 receptors mediate opposite effects of apomorphine on the body temperature of reserpinized mice. Neuropharmacology 1990;29:31–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Meller E, Hizami R, Kreuter L. Hypothermia in mice: D2 dopamine receptor mediation and absence of spare receptors. Pharmacol Biochem Behav 1989;32:141–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Peris J, Boyson SJ, Cass WA, Curella P, Dwoskin LP, Larson G, Lin LH, Yasuda RP, Zahniser NR. Persistence of neurochemical changes in dopamine systems after repeated cocaine administration. J Pharmacol Exp Ther 1990;253:38–44.PubMedGoogle Scholar
  38. 38.
    Kleven MS, Perry BD, Woolverton WL, Seiden LS. Effects of repeated injections of cocaine on D1 and D2 dopamine receptors in rat brain. Brain Res 1990;532:265–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Nunes JL, Sharif NA, Michel AD, Whiting RL. Dopamine D2-receptors mediate hypothermia in mice: ICV and IP effects of agonists and antagonists. Neurochem Res 1991;16:1167–74.PubMedCrossRefGoogle Scholar
  40. 40.
    Barros RC, Branco LG, Carnio EC. Evidence for thermoregulation by dopamine D1 and D2 receptors in the anteroventral preoptic region during normoxia and hypoxia. Brain Res 2004;1030:165–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Wang ZZ, Wang CL, Wu TC, Pan HN, Wang SK, Jiang JD. Autoantibody response to heat shock protein 70 in patients with heatstroke. Am J Med 2001;111:654–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Crandall CG, Vongpatanasin W, Victor RG. Mechanism of cocaine-induced hyperthermia in humans. Ann Intern Med 2002;136:785–91.PubMedGoogle Scholar
  43. 43.
    Skidmore R, Gutierrez JA, Guerriero V, Jr., Kregel KC. HSP70 induction during exercise and heat stress in rats: role of internal temperature. Am J Physiol 1995;268:R92–7.PubMedGoogle Scholar
  44. 44.
    Kregel KC. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol 2002;92:2177–86.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of NeurologyMiller School of Medicine, University of MiamiMiami

Personalised recommendations